Annals of Hematology

, Volume 91, Issue 6, pp 875–888

SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma

  • Giovanni Barosi
  • Giampaolo Merlini
  • Atto Billio
  • Mario Boccadoro
  • Paolo Corradini
  • Monia Marchetti
  • Massimo Massaia
  • Patrizia Tosi
  • Antonio Palumbo
  • Michele Cavo
  • Sante Tura
Original Article

DOI: 10.1007/s00277-012-1445-y

Cite this article as:
Barosi, G., Merlini, G., Billio, A. et al. Ann Hematol (2012) 91: 875. doi:10.1007/s00277-012-1445-y

Abstract

In this project, we produced drug-specific recommendations targeting the use of new agents for multiple myeloma (MM). We used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system which separates the judgments on quality of evidence from the judgment about strength of recommendations. We recommended thalidomide and bortezomib in MM patients candidates to autologous stem cell transplantation (ASCT) (weak positive). We did not recommend novel agents as maintenance therapy after ASCT (weak negative). In patients not candidate to ASCT, thalidomide or bortezomib (strong positive) associated with melphalan and prednisone were recommended. In these patients, no specific course of action could be recommended as for maintenance therapy. In patients who are refractory or relapsing after first-line therapy, we recommended bortezomib and pegylated liposomal doxorubicin, or lenalidomide and dexamethasone combinations (weak positive).

Keywords

Multiple myelomaBortezomibThalidomideLenalidomideGuidelineGRADERecommendations

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Giovanni Barosi
    • 1
    • 10
  • Giampaolo Merlini
    • 2
  • Atto Billio
    • 3
  • Mario Boccadoro
    • 4
  • Paolo Corradini
    • 5
  • Monia Marchetti
    • 6
  • Massimo Massaia
    • 4
  • Patrizia Tosi
    • 7
  • Antonio Palumbo
    • 4
  • Michele Cavo
    • 8
  • Sante Tura
    • 9
  1. 1.Laboratory of Clinical Epidemiology and Center for the Study of MyelofibrosisFondazione IRCCS Policlinico San MatteoPaviaItaly
  2. 2.Amyloidosis Research and Treatment Center and Department of BiochemistryFondazione IRCCS Policlinico San Matteo and University of PaviaPaviaItaly
  3. 3.Department of Ematology, Ospedale CentraleBolzanoItaly
  4. 4.Divisione di Ematologia dell’Università di TorinoAOU S. Giovanni BattistaTurinItaly
  5. 5.Division of HematologyFondazione IRCCS Istituto Nazionale dei TumoriMilanItaly
  6. 6.Unit of Hematology, Hospital “C. Massaia”AstiItaly
  7. 7.Unit of Hematology, Ospedale Infermi RiminiRiminiItaly
  8. 8.Istituto di Ematologia ed Oncologia Medica “Seragnoli”Università di BolognaBolognaItaly
  9. 9.Università di BolognaBolognaItaly
  10. 10.Unità di Epidemiologia Clinica/Centro per lo Studio della MielofibrosiFondazione IRCCS Policlinico S. MatteoPaviaItaly